Acquisition by Kelly Timothy P of 300000 shares of Caribou Biosciences at 5.74 subject to Rule 16b-3
CRBU Stock | USD 1.69 0.10 5.59% |
Slightly above 70% of Caribou Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Caribou Biosciences suggests that many traders are alarmed. Caribou Biosciences' investing sentiment can be driven by a variety of factors including economic data, Caribou Biosciences' earnings reports, geopolitical events, and overall market trends.
Caribou |
Filed transaction by Caribou Biosciences Officer Chief Technology Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Caribou Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Caribou Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Caribou Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Caribou Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Caribou Biosciences Fundamental Analysis
We analyze Caribou Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Caribou Biosciences is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Caribou Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Caribou Biosciences stock to make a market-neutral strategy. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics with similar companies.
Peers
Caribou Biosciences Related Equities
SANA | Sana Biotechnology | 7.36 | ||||
CRSP | Crispr Therapeutics | 1.14 | ||||
ADPT | Adaptive Biotechnologies | 1.11 | ||||
BEAM | Beam Therapeutics | 0.38 | ||||
NTLA | Intellia Therapeutics | 0.66 | ||||
FATE | Fate Therapeutics | 1.19 | ||||
PRME | Prime Medicine, | 1.78 | ||||
VERV | Verve Therapeutics | 2.20 | ||||
EDIT | Editas Medicine | 3.20 |
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.